David Teachey Laboratory

Led by David T. Teachey, MD, researchers in the Teachey Laboratory are focused studying perturbations in leukemic cell signal transduction pathways. Their goal is to identify targeted cancer inhibitors and immunotherapies that can treat children with high-risk leukemias and autoimmune lymphoproliferative syndrome (ALPS). The long-term goal of the research conducted in this laboratory is to develop better therapies, improve cure rates and minimize toxicities for children with high-risk leukemias and ALPS.

Selected Publications

Successful treatment of recurrent autoimmune cytopenias in the context of sinus histiocytosis with massive lymphadenopathy using sirolimus. Pediatr Blood Cancer 63(2): 358-60, February  2016.
Cooper SL, Arceci RJ, Gamper CJ, Teachey DT, Schafer ES.


Atypical chronic myeloid leukemia in two pediatric patients. Pediatr Blood Cancer. 2016 Jan;63(1):156-9.
Freedman JL, Desai AV, Bailey LC, Aplenc R, Burnworth B, Zehentner BK, Teachey DT, Wertheim G.


Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28.
Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT.